In addition, patients who responded to therapy had aggregates of CD3+/CD8+ TILs at the infiltrating tumour edge in their samples before treatment was applied, and also increased number of CD3+/CD8+ TILs after treatment. This evidence concerns the gene CD8A and neoplasm.